GSK plc leans on specialty medicines as analyst views diverge

By Thomas Clarke, Operations & Strategy desk. Reviewed on June 30, 2026 at 3:13 p.m. ET.

GSK plc (ISIN GB0009252882) is highlighting double-digit growth in its Specialty Medicines segment as a key driver of long-term revenue ambitions, with fresh consensus and rating signals showing investors how the story is evolving ahead of upcoming quarters.

According to a detailed overview from Zacks, GSK’s Specialty Medicines business now accounts for more than 40 percent of total sales and grew 14 percent year over year in the first quarter of 2026, supported by HIV, respiratory and oncology therapies.

For US investors accessing GSK via its New York Stock Exchange listing under ticker GSK, that mix between mature franchises and pipeline-driven launches is a central part of the valuation debate.

Specialty Medicines push gathers pace

The latest analysis from Zacks reports that GSK’s Specialty Medicines segment spans four core areas: respiratory, immunology and inflammation, oncology and HIV, and has become the company’s primary growth engine.

The segment delivered £3.2 billion in sales in the first quarter of 2026, with all therapy areas contributing double-digit growth, underscoring how concentrated investment in innovative assets is reshaping the revenue base.

Management guidance cited in the same analysis points to expected low double-digit percentage sales growth at constant exchange rates for Specialty Medicines in 2026, with the company aiming for this unit to exceed 50 percent of total revenues by 2031 as new products mature and more pipeline candidates reach the market.

This trajectory reinforces GSK’s strategy of focusing capital and R&D resources on higher-margin, high-barrier therapies rather than legacy primary-care products, a shift that has been several years in the making.

Analyst expectations and valuation signals

Recent consensus and rating data compiled by MarketScreener show a mixed analyst stance on GSK, including a sell rating from JPMorgan and upbeat commentary from Bernstein that describes the HIV franchise as much more durable and supports higher forecasts.

This divergence in views reflects differing assessments of how sustainable current growth trends are, especially as patents age and competitive pressures in HIV and respiratory medicine remain a constant consideration.

On the earnings side, Zacks reports that the consensus estimate for GSK’s 2026 earnings has edged up from $4.83 to $4.84 per share over the past 30 days, with the 2027 estimate rising from $5.13 to $5.14 per share, suggesting incremental confidence in medium-term profitability.

The same report underlines that GSK’s stock is trading at about 9.87 times forward 12-month earnings, below an industry average of 17.06 and slightly under its five-year mean multiple of 9.92, a valuation profile that some investors may interpret as pricing in execution risks as well as litigation and regulatory uncertainties.

These metrics combine a relatively cautious rating stance from some banks with modestly rising earnings estimates and a discount to the broader sector, setting a nuanced backdrop rather than a uniform bullish or bearish call.

Core franchises and representative products

GSK’s growth strategy is anchored not only in new launches but also in established medicines and vaccines that generate recurring revenue and support ongoing investment.

In the HIV franchise, GSK’s portfolio is built around long-acting regimens and combination therapies designed to improve adherence and reduce resistance, a space where innovation can translate directly into stickier patient relationships and more predictable cash flows.

In respiratory and immunology, inhaled treatments and biologics for asthma and chronic obstructive pulmonary disease sit beside drugs targeting more niche inflammatory conditions, building a spectrum from mass-market products to specialty therapies that command higher prices and require more complex clinical development.

Oncology remains an area of intense pipeline activity, where GSK is seeking to move beyond incremental improvements by investing in mechanisms that can work across tumor types or in selected biomarker-driven patient segments.

Across these categories, the Specialty Medicines framing described by Zacks captures how the company is leaning into products with a stronger scientific edge and clearer competitive moats.

GSK plc stock price and trading context

On the London Stock Exchange, GSK plc recently traded at 2,001.00 pence, which is 12.31 percent below its 52-week high of 2,282.00 pence set on February 18, 2026, according to market data from the Financial Times.

Trading-venue snapshots published by Investing.com show GSK plc quoted around 1,979.50 pence with modest percentage moves and daily volume in the single-digit millions of shares, indicating an actively traded, large-cap name rather than a thinly traded niche stock.

US investors typically gain exposure via the NYSE-listed American depositary receipt under ticker GSK, which carries the same economic interest in the underlying UK shares while trading in US dollars during regular US market hours.

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.